Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK03 Rucaparib
D10982 Rucaparib camsylate (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Rucaparib
D10982 Rucaparib camsylate (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG01864 Rucaparib
D10982 Rucaparib camsylate
Drug classes [BR:br08332]
Antineoplastic
DG02942 PARP inhibitor
D10982 Rucaparib camsylate
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Pentosyltransferases
PARP1
D10982 Rucaparib camsylate (USAN) <US>
PARP2
D10982 Rucaparib camsylate (USAN) <US>
PARP3
D10982 Rucaparib camsylate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10982
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10982
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10982
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG01864 Rucaparib